Join to View Full Profile
1240 Lee StCharlottesville, VA 22908
Phone+1 434-924-9333
Fax+1 434-243-6086
Dr. Keng is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2011 - 2014
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2007 - 2010
Michigan State University College of Human MedicineClass of 2007
Certifications & Licensure
CA State Medical License 2008 - Present
VA State Medical License 2014 - 2026
MI State Medical License 2010 - 2014
OH State Medical License 2011 - 2014
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia.Yesid Alvarado-Valero, Rachel J Cook, Shira N Dinner, Michael Keng, Kebede H Begna
Blood Neoplasia. 2025-08-01 - Real-world analysis of strategies to prevent thrombosis and bleeding in adults with ALL treated with asparaginase.Joseph F Mort, David Brighton, Benjamin Mautner, Eric Pierce, Farid Ghamsari
Blood Vessels, Thrombosis & Hemostasis. 2025-08-01 - Development and Implementation of Oral Anticancer Agent Tools for a Thematic Quality Improvement Program: A Collaboration Between Hematology Oncology Pharmacist Associ...Victoria Nachar, Marjorie Adams Curry, Diana Kostoff, Angela Wood, Karen B Farris
JCO Oncology Practice. 2025-07-01
Abstracts/Posters
- Distance Does Not Matter: Excellent Survival Outcomes for Leukemia Patients in Rural AppalachiaMichael K Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...Michael Keng, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
$13 Million Grant Funds Battle Against Acute Myeloid LeukemiaOctober 1st, 2025
It's Time to Take Action on Quality Improvement MeasuresOctober 21st, 2016- Download Clinical Vignette and Research Abstract CompendiumJanuary 16th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
